{"protocolSection":{"identificationModule":{"nctId":"NCT00745875","orgStudyIdInfo":{"id":"D4320C00035"},"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study","officialTitle":"A Phase II, Double-blind, Placebo Controlled, Randomised Study to Assess the Efficacy and Safety of ZD4054 (Zibotentan) in Combination With Pemetrexed (Alimta®) vs. Pemetrexed Alone in Patients With Non-small Cell Lung Cancer Who Have Failed One Prior Platinum-based Chemotherapy Regimen"},"statusModule":{"statusVerifiedDate":"2012-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-08"},"primaryCompletionDateStruct":{"date":"2010-01","type":"ACTUAL"},"completionDateStruct":{"date":"2010-01","type":"ACTUAL"},"studyFirstSubmitDate":"2008-09-02","studyFirstSubmitQcDate":"2008-09-02","studyFirstPostDateStruct":{"date":"2008-09-03","type":"ESTIMATED"},"resultsFirstSubmitDate":"2012-04-26","resultsFirstSubmitQcDate":"2012-04-26","resultsFirstPostDateStruct":{"date":"2012-06-06","type":"ESTIMATED"},"lastUpdateSubmitDate":"2012-04-26","lastUpdatePostDateStruct":{"date":"2012-06-06","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The aim of this study is to collect initial efficacy and safety data on the use of a new treatment ZD4054 (Zibotentan) when used in combination with pemetrexed (a standard chemotherapy agent) for the treatment of non-small cell lung cancer compared to treatment with pemetrexed alone"},"conditionsModule":{"conditions":["Non Small Cell Lung Cancer","Lung Cancer"],"keywords":["NSCLC","Phase II","ZD4054","Pemetrexed","Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":66,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1","type":"EXPERIMENTAL","description":"ZD4054 + Pemetrexed","interventionNames":["Drug: ZD4054","Drug: Pemetrexed"]},{"label":"2","type":"PLACEBO_COMPARATOR","description":"ZD4054 matched placebo + pemetrexed","interventionNames":["Drug: Pemetrexed","Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"ZD4054","description":"10mg oral tablet, once daily","armGroupLabels":["1"],"otherNames":["Zibotentan"]},{"type":"DRUG","name":"Pemetrexed","description":"500mg2/m IV infusion","armGroupLabels":["1","2"],"otherNames":["Alimta"]},{"type":"DRUG","name":"Placebo","description":"10mg oral tablet, once daily","armGroupLabels":["2"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Time to Death","description":"Median time (in days) from randomisation until death using the Kaplan-Meier method (Calculator for survival probability)","timeFrame":"Patients were followed up for survival every week for the first 3 weeks then every 3 weeks whilst on study medication until the data cut-off (17th January 2010)."}],"secondaryOutcomes":[{"measure":"Progression-free Survival","description":"Median time (in days) from randomisation until disease progression/death using the Kaplan-Meier method","timeFrame":"Tumour assessments for progression were performed at screening, every 3 weeks, Mandatory Tumour Assessment Visit (19 August 2009 ± 3 days), treatment discontinuation"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed locally advanced or metastatic NSCLC on entry into study suitable for pemetrexed therapy\n* Patients that meet one of the following criteria: - progressed following one prior platinum-based chemotherapy regimen for locally advanced or metastatic disease; -progressed within 6 months of adjuvant platinum-based chemotherapy\n* Life expectancy of \\> 12 weeks\n\nExclusion Criteria:\n\n* Prior treatment with pemetrexed in the last 12 months.\n* Prior therapy with an ET receptor antagonist\n* Any recent surgery, unhealed surgical incision, severe concomitant medical condition (eg, unstable cardiac, hepatic or renal disease) or significant laboratory finding which makes it undesirable for the patient to participate","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Thomas Morris, MD","affiliation":"AstraZeneca","role":"STUDY_DIRECTOR"},{"name":"Christos Chouaid, MD, Prof","affiliation":"Hospital Saint-Antoine, Cedex, France","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"research Site","city":"Pleven","country":"Bulgaria","geoPoint":{"lat":43.41791,"lon":24.61666}},{"facility":"Research Site","city":"Sofia","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"Research Site","city":"Varna","country":"Bulgaria","geoPoint":{"lat":43.21912,"lon":27.91024}},{"facility":"Research Site","city":"Jičín","country":"Czechia","geoPoint":{"lat":50.43723,"lon":15.35162}},{"facility":"Research Site","city":"Prague","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Research Site","city":"Cedex","country":"France"},{"facility":"Research Site","city":"Strasbourg","country":"France","geoPoint":{"lat":48.58392,"lon":7.74553}},{"facility":"Research Site","city":"Bucharest","country":"Romania","geoPoint":{"lat":44.43225,"lon":26.10626}},{"facility":"Research Site","city":"Cluj-Napoca","country":"Romania","geoPoint":{"lat":46.76667,"lon":23.6}},{"facility":"Research Site","city":"Chernivtsi","country":"Ukraine","geoPoint":{"lat":48.29045,"lon":25.93241}},{"facility":"Research Site","city":"Kiev","country":"Ukraine","geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Research Site","city":"Sumy","country":"Ukraine","geoPoint":{"lat":50.91741,"lon":34.79906}},{"facility":"Research Site","city":"Uzngorod","country":"Ukraine"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"14 of the 80 enrolled patients were not randomised to treatments groups: 7 patients did not meet one or more of the study inclusion or exclusion criteria, 3 patients failed screening, 2 patients were not included due to investigator decision, 1 patient withdrew consent and 1 patient died.","recruitmentDetails":"80 patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) where the histology was not predominantly of squamous type were recruited between 12th August 2008 and 3rd June 2009.","groups":[{"id":"FG000","title":"Placebo + Pemetrexed","description":"Pemetrexed 500 mg/m2 Intravenous (IV) infusion every 21 days + placebo oral tablet once daily"},{"id":"FG001","title":"ZD4054 + Pemetrexed","description":"ZD4054 10 mg oral tablet once daily + Pemetrexed 500 mg/m2 IV infusion every 21 days"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Started - Number of patients randomised","numSubjects":"36"},{"groupId":"FG001","comment":"Started - Number of patients randomised","numSubjects":"30"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"Completed - Number of patients discontinued study treatment at data cut-off (17th January 2010)","numSubjects":"32"},{"groupId":"FG001","comment":"Completed - Number of patients discontinued study treatment at data cut-off (17th January 2010)","numSubjects":"26"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"}]}],"dropWithdraws":[{"type":"Continuing study treatment","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Placebo + Pemetrexed","description":"Pemetrexed 500 mg/m2 Intravenous (IV) infusion every 21 days + placebo oral tablet once daily"},{"id":"BG001","title":"ZD4054 + Pemetrexed","description":"ZD4054 10 mg oral tablet once daily + Pemetrexed 500 mg/m2 IV infusion every 21 days"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"66"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"56.6","spread":"12.06"},{"groupId":"BG001","value":"57.5","spread":"10.44"},{"groupId":"BG002","value":"57","spread":"11.25"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"19"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"47"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Death","description":"Median time (in days) from randomisation until death using the Kaplan-Meier method (Calculator for survival probability)","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Days","timeFrame":"Patients were followed up for survival every week for the first 3 weeks then every 3 weeks whilst on study medication until the data cut-off (17th January 2010).","groups":[{"id":"OG000","title":"Placebo + Pemetrexed","description":"Pemetrexed 500 mg/m2 Intravenous (IV) infusion every 21 days + placebo oral tablet once daily"},{"id":"OG001","title":"ZD4054 + Pemetrexed","description":"ZD4054 10 mg oral tablet once daily + Pemetrexed 500 mg/m2 IV infusion every 21 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"30"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"193","lowerLimit":"27","upperLimit":"437"},{"groupId":"OG001","value":"146","lowerLimit":"19","upperLimit":"427"}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival","description":"Median time (in days) from randomisation until disease progression/death using the Kaplan-Meier method","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Days","timeFrame":"Tumour assessments for progression were performed at screening, every 3 weeks, Mandatory Tumour Assessment Visit (19 August 2009 ± 3 days), treatment discontinuation","groups":[{"id":"OG000","title":"Placebo + Pemetrexed","description":"Pemetrexed 500 mg/m2 Intravenous (IV) infusion every 21 days + placebo oral tablet once daily"},{"id":"OG001","title":"ZD4054 + Pemetrexed","description":"ZD4054 10 mg oral tablet once daily + Pemetrexed 500 mg/m2 IV infusion every 21 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"30"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87","lowerLimit":"27","upperLimit":"283"},{"groupId":"OG001","value":"110","lowerLimit":"18","upperLimit":"303"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Placebo + Pemetrexed","description":"Pemetrexed 500 mg/m2 Intravenous (IV) infusion every 21 days + placebo oral tablet once daily","seriousNumAffected":7,"seriousNumAtRisk":30,"otherNumAffected":22,"otherNumAtRisk":30},{"id":"EG001","title":"ZD4054 + Pemetrexed","description":"ZD4054 10 mg oral tablet once daily + Pemetrexed 500 mg/m2 IV infusion every 21 days","seriousNumAffected":4,"seriousNumAtRisk":36,"otherNumAffected":20,"otherNumAtRisk":36}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":36}]},{"term":"Febrile Bone Marrow Aplasia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":36}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":36}]},{"term":"Right Ventricular Failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":36}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":36}]},{"term":"Upper Gastrointestinal Haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":36}]},{"term":"Adverse Drug Reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":36}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":36}]},{"term":"Erysipelas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":36}]},{"term":"Lung Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":36}]},{"term":"Metastases To Central Nervous System","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":36}]},{"term":"Renal Failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":36}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":36}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":30},{"groupId":"EG001","numAffected":7,"numAtRisk":36}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":36}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":36}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":5,"numAtRisk":36}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":36}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":36}]},{"term":"Oedema Peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":4,"numAtRisk":36}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":36}]},{"term":"Hypertransaminasaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":36}]},{"term":"Bacterial Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":36}]},{"term":"Body Temperature Increased","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":36}]},{"term":"Brain Natriuretic Peptide Increased","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":3,"numAtRisk":36}]},{"term":"Weight Decreased","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30},{"groupId":"EG001","numAffected":3,"numAtRisk":36}]},{"term":"Alanine Aminotransferase Increased","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":36}]},{"term":"Aspartate Aminotransferase Increased","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":36}]},{"term":"Decreased Appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":36}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":36}]},{"term":"Musculoskeletal Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":36}]},{"term":"Back Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":36}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":3,"numAtRisk":36}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":36}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":36}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":36}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":3,"numAtRisk":36}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":36}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"AstraZeneca can review results communications prior to public release and may within 60 days of receipt require amendments to be made. AstraZeneca can also require that submission or disclosure be delayed for 90 days to allow for the filing of a patent application."},"pointOfContact":{"title":"Gerard Lynch","organization":"AstraZeneca","email":"aztrial_results_posting@astrazeneca.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D008175","term":"Lung Neoplasms"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C511404","term":"ZD4054"},{"id":"D000068437","term":"Pemetrexed"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":true}